Iovance Biotherapeutics, Inc. (LON:0JDK)

Iovance Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	90.86	1.19	-	-	-	-
Cost of Revenue	82.82	10.76	-	-	-	-
Gross Profit	8.04	-9.57	-	-	-	-
Selling, General & Admin	140.42	106.92	104.1	83.66	60.21	40.85
Research & Development	297.58	344.08	294.78	259.04	201.73	166.02
Operating Expenses	438	450.99	398.88	342.7	261.94	206.87
Operating Income	-429.96	-460.56	-398.88	-342.7	-261.94	-206.87
Interest & Investment Income	4.6	9.44	3.46	6.46	4.22	5.9
EBT Excluding Unusual Items	-425.36	-451.12	-395.42	-336.24	-257.72	-200.98
Gain (Loss) on Sale of Investments	9.22	3.61	-0.47	-6.01	-1.87	3.42
Pretax Income	-416.14	-447.52	-395.89	-342.25	-259.58	-197.56
Income Tax Expense	-6.15	-3.48	-	-	-	-
Net Income	-410	-444.04	-395.89	-342.25	-259.58	-197.56
Net Income to Common	-410	-444.04	-395.89	-342.25	-259.58	-197.56
Shares Outstanding (Basic)	278	235	159	153	138	124
Shares Outstanding (Diluted)	278	235	159	153	138	124
Shares Change (YoY)	30.80%	47.64%	3.82%	10.92%	11.23%	27.82%
EPS (Basic)	-1.48	-1.89	-2.49	-2.23	-1.88	-1.59
EPS (Diluted)	-1.48	-1.89	-2.49	-2.23	-1.88	-1.59
Free Cash Flow	-374.08	-384.11	-313.18	-265.52	-251.93	-165.81
Free Cash Flow Per Share	-1.35	-1.63	-1.97	-1.73	-1.82	-1.33
Operating Margin	-473.22%	-38734.99%	-	-	-	-
Profit Margin	-451.25%	-37345.42%	-	-	-	-
Free Cash Flow Margin	-411.72%	-32305.30%	-	-	-	-
EBITDA	-408.32	-449.01	-389.57	-339.59	-260.8	-205.7
D&A For EBITDA	21.64	11.55	9.31	3.11	1.14	1.17
EBIT	-429.96	-460.56	-398.88	-342.7	-261.94	-206.87
Revenue as Reported	90.86	1.19	-	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.